Rising Drug Pricing Pressures And Generic Competition Will Depress Prospects

Published
14 Apr 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$118.00
17.5% overvalued intrinsic discount
16 Aug
US$138.60
Loading
1Y
-31.4%
7D
6.1%

Author's Valuation

US$118.0

17.5% overvalued intrinsic discount

AnalystLowTarget Fair Value

Shared on07 May 25
Fair value Decreased 12%

Shared on23 Apr 25
Fair value Increased 0.10%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 17%

AnalystLowTarget made no meaningful changes to valuation assumptions.